SCHEMBL10133630

SCHEMBL10133630

Cc1cncc(-c2cnc(N3CCOCC3)c(C)n2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 4/20 0.52
ROCK2 O75116 1/20 0.45
ROCK1 Q13464 1/20 0.45
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 2/20 0.41
KMT2A Q03164 2/20 0.41
NOS1 P29475 3/20 0.41
ATR Q13535 1/20 0.41
ATRIP Q8WXE1 1/20 0.41
GAK O14976 1/20 0.40
HCRTR1 O43613 1/20 0.40
HCRTR2 O43614 1/20 0.40
ADK P55263 1/20 0.39
OPRK1 P41145 1/20 0.39
GSK3B P49841 1/20 0.39
DYRK1A Q13627 1/20 0.39
GAA P10253 1/20 0.39
PIK3CA P42336 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7876773 0.83 LRRK2 (0.47) LRRK2ROCK2ROCK1CYP11B1CYP11B2
SCHEMBL441242 0.81 LRRK2 (0.47) LRRK2ROCK2ROCK1MEN1ALDH1A1
SCHEMBL3755666 0.80 NOS1 (0.69) LRRK2NOS1ATRATRIPGAK
SCHEMBL30414390 0.78 CYP11B1 (0.53) LRRK2CYP11B1CYP11B2MEN1ALDH1A1
SCHEMBL11992447 0.72 TGFBR1 (0.51) LRRK2CYP11B1CYP11B2MEN1ALDH1A1
SCHEMBL13473249 0.71 LRRK2 (0.55) LRRK2CYP11B1CYP11B2MEN1ALDH1A1
SCHEMBL14376028 0.70 ALDH1A1 (0.45) LRRK2CYP11B1CYP11B2MEN1ALDH1A1
SCHEMBL13354353 0.70 CYP11B2 (0.63) LRRK2CYP11B1CYP11B2MEN1ALDH1A1
SCHEMBL19406806 0.69 HCRTR1 (0.41) LRRK2CYP11B1CYP11B2ALDH1A1ATR
SCHEMBL13778343 0.69 NOS3 (0.52) LRRK2CYP11B1CYP11B2MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065205-A1 PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065205-A1 PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY5R LRRK2 1099/4885ROCK2 3021/4885ROCK1 3400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.